Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Passage Bio, Inc. - Common Stock (NQ:PASG)

3.370 -0.140 (-3.99%)
Delayed Quote Updated: 3:51 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Passage Bio, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ), Finward Bancorp (Nasdaq – FNWD)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Passage Bio and Remix Therapeutics Announce Merger Agreement
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces 1-for-20 Reverse Stock Split
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Welcomes Tom Kassberg to Board of Directors
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS